Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus
Learning Objectives
